Scientific Publications

The links on this page are not affiliated with Mitsubishi Tanabe Pharma America, Inc. (MTPA). Links to sites outside of MTPA are provided as a resource to the viewer. MTPA accepts no responsibility for the content of linked sites. Some links may direct to third-party websites that require a subscription to access publications.

  • Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis
    —Brooks BR, Berry JD, Ciepielewska M, et al. Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis. eClinicalMedicine. 2022;52:101590. doi:  10.1016/j.eclinm.2022.101590.
    View article
  • Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19)
    —Shefner J, Heiman‐Patterson T, Pioro EP, et al. Long‐term edaravone efficacy in amyotrophic lateral sclerosis: post‐hoc analyses of Study 19 (MCI186‐19). Muscle Nerve. 2020;61(2):218-221. doi:  10.1002/mus.26740.
    View article
  • Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]
    —Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, et al. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PloS One. 2022;17(6):e0258614. doi:  10.1371/journal.pone.0258614.
    View reference
  • Analysis of the US safety data for edaravone (Radicava®) from the third year after launch
    —Genge A, Brooks BR, Oskarsson B, et al. Analysis of the US safety data for edaravone (Radicava®) from the third year after launch. Drugs R D. 2022;22(3):205-211. doi:  10.1007/s40268-022-00391-6.
    View reference
  • Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19
    —Brooks BR, Pioro EP, Katz J, et al. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19. Muscle Nerve. 2022;65(2):180-186. doi:  10.1002/mus.27467.
    View reference
  • Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study
    —Berry JD, Bedlack R, Mathews D, et al. Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(1-2):147-150. doi:  10.1080/21678421.2020.1804939.
    View reference
  • Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool
    —Brooks BR, Pioro EP, Beaulieu D, et al. Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1-2):49-57. doi:  10.1080/21678421.2021.1927102.
    View article
  • Clinical staging in amyotrophic lateral sclerosis: analysis of edaravone Study 19
    —Al-Chalabi A, Chiò A, Merrill C, et al. Clinical staging in amyotrophic lateral sclerosis: analysis of edaravone Study 19. J Neurol Neurosurg Psychiatry. 2021;92(2):165-171. doi:  10.1136/jnnp-2020-323271.
    View article
  • Treatment persistence among amyotrophic lateral sclerosis patients receiving intravenous edaravone: results from a national infusion center
    —Hagan M, Ciepielewska M, Harrison A, et al. Treatment persistence among amyotrophic lateral sclerosis patients receiving intravenous edaravone: results from a national infusion center. Poster presented at virtual 31st International Symposium on ALS/MND; December 9-11, 2020.
    View poster
  • Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis
    —Palumbo JM, Hubble J, Apple S, et al. Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):421-431.  doi:  10.1080/21678421.2019.1599955.
    View article
  • A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
    —The Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):11-19. doi:  10.1080/21678421.2017.1363780.
    View article
  • Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
    —The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512. doi:  1016/S1474-4422(17)30115-1.
    View article

The studies referenced herein are provided for general information only and are not intended as statements about the safety or efficacy of any product.